Covidien (Dublin, Ireland) recently reported final 12-month results from its DEFINITIVE LE study (determination of effectiveness of SilverHawk/TurboHawk peripheral plaque excision systems for the treatment of infrainguinal vessels/lower extremities) study. With about 800 patients enrolled at 47 centers in the U.S. and Europe, the study is the largest peripheral atherectomy study conducted with independent physician review of the outcomes, Covidien noted. Read More
